BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8695248)

  • 1. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
    Martoni A; Angelelli B; Guaraldi M; Strocchi E; Pannuti F
    Eur J Cancer; 1996 Jan; 32A(1):82-5. PubMed ID: 8695248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
    Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
    Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
    Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F
    Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
    Gebbia V; Cannata G; Testa A; Curto G; Valenza R; Cipolla C; Latteri MA; Gebbia N
    Cancer; 1994 Oct; 74(7):1945-52. PubMed ID: 8082100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
    Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
    Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
    Navari R; Gandara D; Hesketh P; Hall S; Mailliard J; Ritter H; Friedman C; Fitts D
    J Clin Oncol; 1995 May; 13(5):1242-8. PubMed ID: 7738628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.
    Ann Oncol; 1995 Oct; 6(8):805-10. PubMed ID: 8589019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
    Noble A; Bremer K; Goedhals L; Cupissol D; Dilly SG
    Eur J Cancer; 1994; 30A(8):1083-8. PubMed ID: 7654434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.
    Ruff P; Paska W; Goedhals L; Pouillart P; Rivière A; Vorobiof D; Bloch B; Jones A; Martin C; Brunet R
    Oncology; 1994; 51(1):113-8. PubMed ID: 8265095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
    Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
    Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
    Jørgensen M; Victor MA
    Acta Oncol; 1996; 35(2):159-63. PubMed ID: 8639310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
    Roila F; Tonato M; Cognetti F; Cortesi E; Favalli G; Marangolo M; Amadori D; Bella MA; Gramazio V; Donati D
    J Clin Oncol; 1991 Apr; 9(4):675-8. PubMed ID: 1829757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
    Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
    Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
    Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy.
    Tsavaris N; Fountzilas G; Mylonakis N; Athanassiadis A; Kosmas C; Karakousis C; Bacoyiannis C; Kosmidis P
    Oncology; 1998; 55(6):513-6. PubMed ID: 9778615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study.
    Bonneterre J; Hecquet B
    Bull Cancer; 1995 Dec; 82(12):1038-43. PubMed ID: 8745670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.